The global cancer cell market include various therapies used for the treatment of various cancers such as lung cancer, breast cancer, and others. There are various therapies for treatment of cancer such as chemotherapy, radiation therapy, immunotherapy, hormone therapy, targeted drug therapy and others. The types of cancer such as carcinomas, sarcomas, leukemia, and others are caused due day to day lifestyles, and or more often, caused by carcinogens (cancer causing substances) such as tobacco etc.
Key players are focusing on research and development for treatment of cancers such as small cell lung cancer to strengthen their position in the global cancer cell market. For instance, in December 2019, Roche announced that the U.S. Food and Drug Administration (FDA) approved its Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane) for the initial (first-line) treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) with no epidermal growth factor receptor (EGFR) mutations and anaplastic large-cell lymphoma kinase (ALK) genomic tumor aberrations.
- This report studies the current scenario as well as the future potential of the global cancer cell market. The market for cancer cell market is segmented on basis of cancer cell type, application, end user, and region.
- This report provides in-depth analysis of the global cancer cell market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2020-2027)
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by leading players.
- It profiles leading players in the global cancer cell market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
- The global cancer cell market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
- Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global cancer cell market
-
- Carcinomas
- Sarcomas
- Leukemia
- Others
-
- Chemotherapy
- Radiation Therapy
- Immunotherapy
- Hormone Therapy
- Targeted Drug Therapy
- Others
-
- Hospitals & Clinics
- Specialty Clinics
- Diagnostic Laboratories
-
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
-
- Abbott Laboratories
- Novartis International AG
- Arcellx
- Autolus Therapeutics
- Kite Pharma
- Cellectis
- Celyad Oncology
- Crescendo Biologics Limited
- GammaDelta Therapeutics Ltd.
- Bio-Rad Laboratories Inc
- QIAGEN Inc
- Thermo Fisher Scientific
- Merck Millipore
- Siemens Healthineers AG
- GE Healthcare
